A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease

Salvatore Accomando, Mario Cottone, Antonio Carroccio, Mario Cottone, Michele Citrano, Sebastiano Siringo, Nunzio Belluardo, Filippo Mocciaro, Sara Renna, Rosalba Orlando, Giulia Rizzuto, Fabio Salvatore Macaluso, Salvatore Accomando, Antonio Carroccio, Claudio Romano, Marco Ventimiglia, Concetta Ferracane, Giovanni Magrì, Roberto Vassallo, Carmelo BertolamiAntonino Trovatello, Serena Porcari, Salvatore Genova, Antonio Carroccio, Nunzio Belluardo, Gaetano Inserra, Roberto Di Mitri, Antonio Carlo Privitera, Antonio Magnano, Ambrogio Orlando, Walter Fries, Maria Cappello, Giuseppe Scarpulla

Risultato della ricerca: Article

4 Citazioni (Scopus)

Abstract

Background and Aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naïve and non-naïve patients. Results A total of 632 patients [735 total treatments] were included. Among naïve patients, a clinical benefit [the sum of steroid-free remission plus clinical response] was achieved in 81.8% patients treated with ADA and in 77.6% patients treated with IFX (adjusted odds ratio [OR]: 1.23, 95% CI 0.63-2-44, p = 0.547] at 12 weeks; after 1 year, a clinical benefit was achieved in 69.2% of patients treated with ADA and in 64.5% patients treated with IFX [adjusted OR: 1.10, 95% CI 0.61-1.96, p = 0.766]. Among non-naïve patients, a clinical benefit was achieved in 61.7% of patients treated with ADA and in 68.1% of patients treated with IFX [adjusted OR: 0.72, 95% CI 0.21-2.44, p = 0.600] at 12 weeks; after 1 year, a clinical benefit was achieved in 48.9% of patients treated with ADA and in 40.4% patients treated with IFX [adjusted OR: 1.23, 95% CI 0.54-2.86, p = 0.620]. Conclusions In this propensity score-matched comparison of ADA and IFX in CD, both drugs showed high rates of clinical benefit, without significant differences between them.
Lingua originaleEnglish
pagine (da-a)209-217
Numero di pagine9
RivistaJournal of Crohn's and Colitis
Volume13
Stato di pubblicazionePublished - 2019

Fingerprint

Propensity Score
Inflammatory Bowel Diseases
Crohn Disease
Tumor Necrosis Factor-alpha
Odds Ratio
Adalimumab
Infliximab
Biological Products

All Science Journal Classification (ASJC) codes

  • Gastroenterology

Cita questo

A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease. / Accomando, Salvatore; Cottone, Mario; Carroccio, Antonio; Cottone, Mario; Citrano, Michele; Siringo, Sebastiano; Belluardo, Nunzio; Mocciaro, Filippo; Renna, Sara; Orlando, Rosalba; Rizzuto, Giulia; Macaluso, Fabio Salvatore; Accomando, Salvatore; Carroccio, Antonio; Romano, Claudio; Ventimiglia, Marco; Ferracane, Concetta; Magrì, Giovanni; Vassallo, Roberto; Bertolami, Carmelo; Trovatello, Antonino; Porcari, Serena; Genova, Salvatore; Carroccio, Antonio; Belluardo, Nunzio; Inserra, Gaetano; Di Mitri, Roberto; Privitera, Antonio Carlo; Magnano, Antonio; Orlando, Ambrogio; Fries, Walter; Cappello, Maria; Scarpulla, Giuseppe.

In: Journal of Crohn's and Colitis, Vol. 13, 2019, pag. 209-217.

Risultato della ricerca: Article

Accomando, S, Cottone, M, Carroccio, A, Cottone, M, Citrano, M, Siringo, S, Belluardo, N, Mocciaro, F, Renna, S, Orlando, R, Rizzuto, G, Macaluso, FS, Accomando, S, Carroccio, A, Romano, C, Ventimiglia, M, Ferracane, C, Magrì, G, Vassallo, R, Bertolami, C, Trovatello, A, Porcari, S, Genova, S, Carroccio, A, Belluardo, N, Inserra, G, Di Mitri, R, Privitera, AC, Magnano, A, Orlando, A, Fries, W, Cappello, M & Scarpulla, G 2019, 'A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease', Journal of Crohn's and Colitis, vol. 13, pagg. 209-217.
Accomando, Salvatore ; Cottone, Mario ; Carroccio, Antonio ; Cottone, Mario ; Citrano, Michele ; Siringo, Sebastiano ; Belluardo, Nunzio ; Mocciaro, Filippo ; Renna, Sara ; Orlando, Rosalba ; Rizzuto, Giulia ; Macaluso, Fabio Salvatore ; Accomando, Salvatore ; Carroccio, Antonio ; Romano, Claudio ; Ventimiglia, Marco ; Ferracane, Concetta ; Magrì, Giovanni ; Vassallo, Roberto ; Bertolami, Carmelo ; Trovatello, Antonino ; Porcari, Serena ; Genova, Salvatore ; Carroccio, Antonio ; Belluardo, Nunzio ; Inserra, Gaetano ; Di Mitri, Roberto ; Privitera, Antonio Carlo ; Magnano, Antonio ; Orlando, Ambrogio ; Fries, Walter ; Cappello, Maria ; Scarpulla, Giuseppe. / A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease. In: Journal of Crohn's and Colitis. 2019 ; Vol. 13. pagg. 209-217.
@article{bbdd4a9762524f9eb5cc98d9146c04a7,
title = "A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-na{\"i}ve and Non-na{\"i}ve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease",
abstract = "Background and Aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-na{\"i}ve and non-na{\"i}ve patients. Results A total of 632 patients [735 total treatments] were included. Among na{\"i}ve patients, a clinical benefit [the sum of steroid-free remission plus clinical response] was achieved in 81.8{\%} patients treated with ADA and in 77.6{\%} patients treated with IFX (adjusted odds ratio [OR]: 1.23, 95{\%} CI 0.63-2-44, p = 0.547] at 12 weeks; after 1 year, a clinical benefit was achieved in 69.2{\%} of patients treated with ADA and in 64.5{\%} patients treated with IFX [adjusted OR: 1.10, 95{\%} CI 0.61-1.96, p = 0.766]. Among non-na{\"i}ve patients, a clinical benefit was achieved in 61.7{\%} of patients treated with ADA and in 68.1{\%} of patients treated with IFX [adjusted OR: 0.72, 95{\%} CI 0.21-2.44, p = 0.600] at 12 weeks; after 1 year, a clinical benefit was achieved in 48.9{\%} of patients treated with ADA and in 40.4{\%} patients treated with IFX [adjusted OR: 1.23, 95{\%} CI 0.54-2.86, p = 0.620]. Conclusions In this propensity score-matched comparison of ADA and IFX in CD, both drugs showed high rates of clinical benefit, without significant differences between them.",
keywords = "Adalimumab, infliximab, propensity score",
author = "Salvatore Accomando and Mario Cottone and Antonio Carroccio and Mario Cottone and Michele Citrano and Sebastiano Siringo and Nunzio Belluardo and Filippo Mocciaro and Sara Renna and Rosalba Orlando and Giulia Rizzuto and Macaluso, {Fabio Salvatore} and Salvatore Accomando and Antonio Carroccio and Claudio Romano and Marco Ventimiglia and Concetta Ferracane and Giovanni Magr{\`i} and Roberto Vassallo and Carmelo Bertolami and Antonino Trovatello and Serena Porcari and Salvatore Genova and Antonio Carroccio and Nunzio Belluardo and Gaetano Inserra and {Di Mitri}, Roberto and Privitera, {Antonio Carlo} and Antonio Magnano and Ambrogio Orlando and Walter Fries and Maria Cappello and Giuseppe Scarpulla",
year = "2019",
language = "English",
volume = "13",
pages = "209--217",
journal = "Journal of Crohn's and Colitis",
issn = "1873-9946",
publisher = "Elsevier",

}

TY - JOUR

T1 - A Propensity Score-matched Comparison of Infliximab and Adalimumab in Tumour Necrosis Factor-α Inhibitor-naïve and Non-naïve Patients with Crohn's Disease: Real-Life Data from the Sicilian Network for Inflammatory Bowel Disease

AU - Accomando, Salvatore

AU - Cottone, Mario

AU - Carroccio, Antonio

AU - Cottone, Mario

AU - Citrano, Michele

AU - Siringo, Sebastiano

AU - Belluardo, Nunzio

AU - Mocciaro, Filippo

AU - Renna, Sara

AU - Orlando, Rosalba

AU - Rizzuto, Giulia

AU - Macaluso, Fabio Salvatore

AU - Accomando, Salvatore

AU - Carroccio, Antonio

AU - Romano, Claudio

AU - Ventimiglia, Marco

AU - Ferracane, Concetta

AU - Magrì, Giovanni

AU - Vassallo, Roberto

AU - Bertolami, Carmelo

AU - Trovatello, Antonino

AU - Porcari, Serena

AU - Genova, Salvatore

AU - Carroccio, Antonio

AU - Belluardo, Nunzio

AU - Inserra, Gaetano

AU - Di Mitri, Roberto

AU - Privitera, Antonio Carlo

AU - Magnano, Antonio

AU - Orlando, Ambrogio

AU - Fries, Walter

AU - Cappello, Maria

AU - Scarpulla, Giuseppe

PY - 2019

Y1 - 2019

N2 - Background and Aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naïve and non-naïve patients. Results A total of 632 patients [735 total treatments] were included. Among naïve patients, a clinical benefit [the sum of steroid-free remission plus clinical response] was achieved in 81.8% patients treated with ADA and in 77.6% patients treated with IFX (adjusted odds ratio [OR]: 1.23, 95% CI 0.63-2-44, p = 0.547] at 12 weeks; after 1 year, a clinical benefit was achieved in 69.2% of patients treated with ADA and in 64.5% patients treated with IFX [adjusted OR: 1.10, 95% CI 0.61-1.96, p = 0.766]. Among non-naïve patients, a clinical benefit was achieved in 61.7% of patients treated with ADA and in 68.1% of patients treated with IFX [adjusted OR: 0.72, 95% CI 0.21-2.44, p = 0.600] at 12 weeks; after 1 year, a clinical benefit was achieved in 48.9% of patients treated with ADA and in 40.4% patients treated with IFX [adjusted OR: 1.23, 95% CI 0.54-2.86, p = 0.620]. Conclusions In this propensity score-matched comparison of ADA and IFX in CD, both drugs showed high rates of clinical benefit, without significant differences between them.

AB - Background and Aims There is an unmet need to better understand the effectiveness of different biologics in inflammatory bowel diseases. We aimed at performing a multicentre, real-life comparison of the effectiveness of infliximab [IFX] and adalimumab [ADA] in Crohn's disease [CD]. Methods Data of consecutive patients with CD treated with IFX and ADA from January 2013 to May 2017 were extracted from the cohort of the Sicilian Network for Inflammatory Bowel Disease. We used propensity score-matching accounting for the main baseline characteristics in TNF-α inhibitor-naïve and non-naïve patients. Results A total of 632 patients [735 total treatments] were included. Among naïve patients, a clinical benefit [the sum of steroid-free remission plus clinical response] was achieved in 81.8% patients treated with ADA and in 77.6% patients treated with IFX (adjusted odds ratio [OR]: 1.23, 95% CI 0.63-2-44, p = 0.547] at 12 weeks; after 1 year, a clinical benefit was achieved in 69.2% of patients treated with ADA and in 64.5% patients treated with IFX [adjusted OR: 1.10, 95% CI 0.61-1.96, p = 0.766]. Among non-naïve patients, a clinical benefit was achieved in 61.7% of patients treated with ADA and in 68.1% of patients treated with IFX [adjusted OR: 0.72, 95% CI 0.21-2.44, p = 0.600] at 12 weeks; after 1 year, a clinical benefit was achieved in 48.9% of patients treated with ADA and in 40.4% patients treated with IFX [adjusted OR: 1.23, 95% CI 0.54-2.86, p = 0.620]. Conclusions In this propensity score-matched comparison of ADA and IFX in CD, both drugs showed high rates of clinical benefit, without significant differences between them.

KW - Adalimumab

KW - infliximab

KW - propensity score

UR - http://hdl.handle.net/10447/364555

UR - https://academic.oup.com/ecco-jcc/issue

M3 - Article

VL - 13

SP - 209

EP - 217

JO - Journal of Crohn's and Colitis

JF - Journal of Crohn's and Colitis

SN - 1873-9946

ER -